托珠单抗在结缔组织病相关间质性肺病治疗中的进展及展望
Progress and prospects of tocilizumab in treatment of connective tissue disease-associated interstitial lung disease
李芝谕 1陈哲 2王钱 2李可天 2程永静2
作者信息
- 1. 北京医院风湿免疫科国家老年医学中心中国医学科学院老年医学研究院,北京 100730;北京大学第五临床医学院,北京 100730
- 2. 北京医院风湿免疫科国家老年医学中心中国医学科学院老年医学研究院,北京 100730
- 折叠
摘要
结缔组织病(connective tissue disease,CTD)是一类累及多个器官和系统的自身免疫性疾病,肺部是其常见受累部位.间质性肺疾病(interstitial lung disease,ILD)作为CTD的主要临床表现之一,常表现为肺间质的炎症或纤维化,导致患者肺功能受损,出现呼吸困难,生活质量降低.白细胞介素-6(interleukin-6,IL-6)可促进炎症反应,促进成纤维细胞增殖和胶原合成,影响纤维化过程,在结缔组织病相关间质性肺病(connective tissue disease-associated interstitial lung disease,CTD-ILD)的发病机制中发挥着重要作用.托珠单抗是IL-6受体拮抗剂,近年来被广泛用于类风湿关节炎等CTD治疗,在CTD-ILD中也取得了一定的疗效.本文介绍了托珠单抗在CTD-ILD治疗中的进展,以期为CTD-ILD治疗策略的制定提供理论依据.
Abstract
Connective tissue diseases(CTDs)are a group of autoimmune diseases that influence multiple organs and systems,with the lung being a commonly affected site.Interstitial lung disease(ILD)is one of the main clinical manifestations of CTD and is characterized by inflammation or fibrosis of the lung interstitium,leading to impaired lung function,respiratory difficulties,and reduced quality of life.Interleukin-6(IL-6)promotes inflammatory responses,stimulates fibroblast proliferation and collagen synthesis,and plays a crucial role in the pathogenesis of connective tissue disease-associated interstitial lung disease(CTD-ILD).Tocilizumab,an IL-6 receptor antagonist,has been widely used in the treatment of CTDs such as rheumatoid arthritis in recent years,and has also shown promising efficacy in the treatment of CTD-ILD.This article reviews the progress of Tocilizumab in the treatment of CTD-ILD,aiming to provide a theoretical basis for the treatment strategies of CTD-ILD.
关键词
结缔组织病/间质性肺病/托珠单抗Key words
Connective tissue disease/Interstitial lung disease/Tocilizumab引用本文复制引用
基金项目
中央高水平医院临床科研业务费(BJ-2021-235)
中央高水平医院临床科研业务费(BJ-2021-192)
出版年
2024
国家科技期刊平台
NSTL
万方数据